Genomic Health's Board Approves $30M Share Repurchase Program | GenomeWeb

NEW YORK (GenomeWeb News) – Genomic Health's board has approved a $30 million share repurchase program, the Redwood City, Calif.-based firm said in a document filed with the US Securities and Exchange Commission today.

Repurchases made under the program will be funded using the firm's working capital. As of Sept. 30, Genomic Health had cash and cash equivalents, and investments and marketable securities totaling $127 million. It had about 30.8 million shares of common stock outstanding as of Nov. 30.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.